SCHEMBL3483971

SCHEMBL3483971

Cc1csc2c(Cl)cc(O)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.40
CHRM1 P11229 1/20 0.40
ALOX15 P16050 1/20 0.40
MAOA P21397 1/20 0.40
TBXA2R P21731 1/20 0.40
ADRA1A P35348 1/20 0.40
HTR2B P41595 1/20 0.40
CYP2A6 P11509 1/20 0.39
HSD17B10 Q99714 2/20 0.38
HPGD P15428 1/20 0.38
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38
ESR1 P03372 4/20 0.35
ESR2 Q92731 4/20 0.35
ALDH1A1 P00352 2/20 0.32
HCRTR1 O43613 1/20 0.32
LMNA P02545 1/20 0.32
POLB P06746 1/20 0.32
MAPT P10636 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7470456 0.80 CYP2A6 (0.50) CYP3A4CYP2A6HSD17B10ALDH1A1KCNA3
SCHEMBL3483833 0.77 ESR1 (0.34) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL3483704 0.74 CYP2A6 (0.37) CYP3A4MAOACYP2A6ALDH1A1
SCHEMBL10729992 0.73 CYP2A6 (0.39) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL2089129 0.72 CYP2A6 (0.41) CYP3A4CYP2A6KCNA3
SCHEMBL7481017 0.69 CYP2A6 (0.52) CYP2A6KCNA3
SCHEMBL3483268 0.68 MCL1 (0.34) CYP2A6POLB
SCHEMBL29908309 0.68 CYP2A6 (0.42) CYP2A6ALDH1A1KCNA3
SCHEMBL787846 0.68 CYP2A6 (0.42) CYP2A6ALDH1A1KCNA3
SCHEMBL23218344 0.65 CYP2A6 (0.32) CYP2A6HPGDLMNAGPR35KCNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2049200-B1 NOVEL INHIBITORS OF BETA-LACTAMASE METHYLGENE INC (CA) 2015-04-29 EP disclosed
US-8440643-B2 Inhibitors of beta-lactamase METHYLGENE INC. (CA) 2013-05-14 US disclosed
US-20100279983-A1 NOVEL INHIBITORS OF BETA-LACTAMASE METHYLGENE INC. 2010-11-04 US disclosed
EP-2049200-A2 NOVEL INHIBITORS OF BETA-LACTAMASE MethylGene Inc. (CA) 2009-04-22 EP disclosed
WO-2008073142-A2 NOVEL INHIBITORS OF BETA-LACTAMASE MERCK & CO., INC. (US) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100279983-A1 NOVEL INHIBITORS OF BETA-LACTAMASE MGAM, MGAM2, PGLS CYP3A4 1281/4885CHRM1 1823/4885ALOX15 2361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.